News
Yale Researchers Make Progress in Advanced Lung Cancer Immunotherapy Recognition and Treatment
A recent Yale study found that a newly developed drug could show promise in slowing the progression of non-small cell lung cancer in patients for whom previous treatments had not been effective.
Presented at the World Conference on Lung Cancer in Singapore in September, the study found that an immunotherapy medication called NC318 could increase the effectiveness of existing cancer treatments and provide an alternative treatment for patients who did not respond to prior immunotherapy.
“In the end, we saw 28% of our patients who had, what we felt, was benefit from this therapy,” said Scott Gettinger, Chief of Thoracic Oncology at the Yale Cancer Center and the study’s lead author. “Which is promising, considering we don’t have anything else. If what we see early on pans out, then this offers a potential salvage therapy for patients who progressed after chemotherapy and immunotherapy, which is the majority of our patients.”
Source: Yale Daily News